Trial Profile
Switching from natalizumab to fingolimod in patients with relapsing-remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms ENIGM
- 15 Dec 2015 New trial record